IM Cannabis (IMCC) Other financing activities (2020 - 2026)

IM Cannabis (IMCC) posted quarterly Other financing activities of $316475.3 for Q1 2026, up 139.85% quarter-over-quarter from -$794212.1 in Q3 2025.

IM Cannabis (IMCC) Other financing activities (2020 - 2026) Analysis & Trends

IM Cannabis' Other financing activities history runs 7 years deep, the most recent figure standing at $316475.3 for Q1 2026.

In Q1 2026, Other financing activities changed N/A year-over-year to $316475.3; the TTM figure through Mar 2026 stood at -$479668.0 (changed N/A YoY), while the FY2024 annual figure was -$46745.6, down 102.58% from the prior year.
Other financing activities for Q1 2026 stood at $316475.3, up from -$794212.1 in the prior quarter.
The five-year high for Other financing activities was $10.0 million in Q4 2022, with the low at -$3.0 million in Q4 2023.
The 5-year median for Other financing activities is $65124.7 (2022), against an average of $1.2 million.
The sharpest annual moves came in 2022 and 2023: Other financing activities soared 8649.61% in 2022, then plunged 21076.09% in 2023.
IM Cannabis' Other financing activities stood at $10.0 million in 2022, then tumbled by 130.39% to -$3.0 million in 2023, then surged by 104.24% to $128680.7 in 2024, then sank by 717.2% to -$794212.1 in 2025, then surged by 139.85% to $316475.3 in 2026.
Business Quant data shows IMCC's Other financing activities at $316475.3 in Q1 2026, -$794212.1 in Q3 2025, and $128680.7 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	IM Cannabis	554,496.00	-614,474.17	1.09 Mn

Download Data